Comments on: Poniard Pharmaceuticals – Platinum Rediscovered (Part II) http://www.hammerstockblog.com/poniard-pharmaceuticals-%e2%80%93-platinum-rediscovered-part-ii/ Biotech stock reviews Sun, 14 Mar 2010 02:22:43 +0000 http://wordpress.org/?v=2.3.1 By: Ohad Hammer http://www.hammerstockblog.com/poniard-pharmaceuticals-%e2%80%93-platinum-rediscovered-part-ii/#comment-1041 Ohad Hammer Tue, 15 Sep 2009 15:28:59 +0000 http://www.hammerstockblog.com/poniard-pharmaceuticals-%e2%80%93-platinum-rediscovered-part-ii/#comment-1041 Thanks, Mitch Unfortunately, I haven't been following PARD for the past year or so due to timing constraints. In general, their clinical strategy is very good in terms of identifying a clinical need and picking the right indications. I have two issues with the ongoing SCLC phase III trial: 1) They jumped straight to phase III without doing a smaller randomized phase two, so all the data we have is from two small (yet consistent) single arm studies. 2) Picoplatin might face competition from CELG's amrubicin that could reach the market shortly after picoplatin does. ohad Thanks, Mitch

Unfortunately, I haven’t been following PARD for the past year or so due to timing constraints.
In general, their clinical strategy is very good in terms of identifying a clinical need and picking the right indications. I have two issues with the ongoing SCLC phase III trial:
1) They jumped straight to phase III without doing a smaller randomized phase two, so all the data we have is from two small (yet consistent) single arm studies.
2) Picoplatin might face competition from CELG’s amrubicin that could reach the market shortly after picoplatin does.

ohad

]]> By: Mitch Wise http://www.hammerstockblog.com/poniard-pharmaceuticals-%e2%80%93-platinum-rediscovered-part-ii/#comment-1038 Mitch Wise Sun, 13 Sep 2009 06:06:16 +0000 http://www.hammerstockblog.com/poniard-pharmaceuticals-%e2%80%93-platinum-rediscovered-part-ii/#comment-1038 Just curious, are you still long PARD? I am and have been reading everything I can get my hands on, including the subtleties of Picoplatin's effect on sensitive SCLC patients (2nd line) vs refactory/resistant, in order to gauge the risk involved with them meeting, or missing, their phase III target This was a great piece you wrote. I'm sure shareholders would love to hear an updated perspective. Just curious, are you still long PARD? I am and have been reading everything I can get my hands on, including the subtleties of Picoplatin’s effect on sensitive SCLC patients (2nd line) vs refactory/resistant, in order to gauge the risk involved with them meeting, or missing, their phase III target

This was a great piece you wrote. I’m sure shareholders would love to hear an updated perspective.

]]>